High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study

1

Vitreoretinal lymphoma (VRL) is a rare, indolent disease with a high risk of developing central nervous system lymphoma, leading to poor long-term prognosis.
2

High-dose chemotherapy with autologous haematopoietic stem cell transplantation (HCT-ASCT) is considered a justified treatment for isolated VRL in France.
3

A retrospective analysis of 38 patients treated with HCT-ASCT showed that 87% achieved a complete response after the procedure.
4

The study utilized data from the French LOC network, centralizing information from 28 centers involved in managing primary central nervous system lymphoma.
5

The treatment approach for VRL remains controversial, necessitating a multidisciplinary strategy due to the disease's rarity and complexity.

Bone Marrow Transplantation

by Adam Mainguy, Carole Soussain, Valérie Touitou, Amin Bennedjai, Laurent Kodjikian, Hervé Ghesquières, Gandhi Damaj, Rémy Gressin, Jean-Baptiste Ducloyer, Olivier Chinot, Anaïs Vautier, Cécile Moluçon-Chabrot, Guido Ahle, Luc Taillandier, Jean Pierre Marolleau, Adrien Chauchet, Fabrice Jardin, Nathalie Cassoux, Denis Malaise, Adélaïde Toutée, Sara Touhami, Magali Le Garff-Tavernier, Khê Hoang-Xuan, Sylvain Choquet, Caroline Houillier
November 19, 2024

1